PATENT CLAIM ANALYSIS

Application Number: 16109643
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "309000"]

Abstract:
Provided herein are compounds of Formula I, or a pharmaceutically acceptable salt thereof: which are useful as PARP inhibitors, as well as pharmaceutical compositions comprising them and methods for their use in treating disorders.

Claim (Index 16):
The method of  claim 15  wherein the DNA-damaging agent is selected from the group of cisplatin, carboplatin, oxaliplatin, picoplatin, dicycloplatin, eptaplatin, lobaplatin, miriplatin, nedaplatin, satraplatin, triplatin tetranitrate, doxorubicin, daunorubicin, epirubicin, idarubicin, procarbazine, altretamine, bleomycin, carmustine, lomustine, streptozocin, semustine, temozolomide, 5-fluorouracil, capecitabine, floxuridine, gemcitabine, 6-mercaptopurine, 8-azaguanine, fludarabine, cladribine, methotrexate, aminopterin, pemetrexed), ralitrexed, etoposide, aphidicoliin, hydroxyurea, Inotuzumab ozogamicin, cyclophosphamide, chlormethine, Melphalan, Chlorambucil, Ifosfamide, and Bendamustine.

Metadata:
- Claim Count in Document: 27.0
- Percentile: 96.0
- Lexical Diversity: 1.11765
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['11535127', '10271715', '11567352', '14647088', '14991815']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7611315966378092
- 35 USC 102 Novelty (BERT): 0.527760177891204
- Combined Prediction Score: 0.7377944547631488
- Mean Citation Score: 283.654396
- Max Citation Score: 287.6168
- Similarity Product: 170.2945541607857

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test